SAN DIEGO, May 27, 2011 /PRNewswire/ — TriLink
BioTechnologies, Inc. (TriLink), a leader in manufacturing high
quality oligonucleotides and nucleoside triphosphates, announced
today the award of their CleanAmp™ Primer patent by the
European Patent Office (EPO Patent no. 2032714).
First launched in March of 2008, CleanAmp™
Primers pioneered TriLink’s CleanAmp™
line of next generation Hot Start PCR products. The technology
consists of thermolabile chemical modifications which allow for
primer-based Hot Start activation in PCR. These modifications
prevent primer extension at the lower temperatures of PCR set up
and manipulation, eliminating primer dimer and mis-priming events.
The performance of CleanAmp™ Primers can be applied to
critical applications such as molecular diagnostics, forensics,
detection of infectious agents and gene expression validation.
TriLink sought patent protection in Europe in 2007, filing the
patent application titled Chemically Modified Oligonucleotide
Primers for Nucleic Acid Amplification with the European Patent
Office (EPO), under the patent application number 0777161.6, now
EPO Patent no. 2032714, published on March 16, 2011.
Gerald Zon, co-inventor, commented, “CleanAmp™ Primers
provide flexibility for use with either low-cost polymerases, or to
further enhance performance of other PCR components, such as Hot
Start polymerases or TriLink’s CleanAmp™
dNTPs, in especially demanding applications.”
“The CleanAmp™ Primers are the foundation of the
CleanAmp™ product line, and paved the way for the innovative
solutions of CleanAmp™ dNTPs and CleanAmp™
7-deaza-dGTP. They continue to inspire us as we apply our nucleic
acid chemistry e
‘/>”/>
SOURCE
